In this Ask the Expert segment, a Patient Power community member wants to know Are there recommendations for vaccines for…
Browsing: Acute Lymphoblastic Leukemia
During this Ask the Expert segment, a community member with essential thrombocythemia (ET) wants to know about increased risk for…
Dr. Abdulraheem Yacoub explains how CAR-T cell therapy targets cancer cells in the body and what the future holds for…
The ways in which healthcare providers function must change to keep up with increasing demand. In this video, Bryn Thomas…
Communicating and learning from shared experiences aids in the improvement of medical practices. In this interview, Bryn Thomas of The…
In todays digitally advanced society, large volumes of patient-level data can be collected and compiled. With an ever-increasing demand upon…
How is the role of the pharmacist changing as treatments in hematological cancers develop? Susannah Koontz Webb, PharmD, BCOP, FHOP,…
Susannah Koontz Webb, PharmD, BCOP, FHOP, President of the Hematology Oncology Pharmacy Association (HOPA) discusses her session on Collaborative Projects…
During the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK, we met with Susannah Koontz Webb,…
An important question regarding the use of biosimilar rituximab is whether rapid infusion rates are safe, as they are for…
David Irvine from the Beatson Institute, Glasgow, UK discusses introducing CAR-T cells and other cellular therapies into clinical practice and…
Several major breakthroughs in the treatment of amyloid light-chain (AL) amyloidosis were presented at the American Society of Hematology (ASH)…
This is an exciting time in hemeonc, with new treatment paradigms across a range of malignant hematologies, including multiple myeloma…
The use of frontline autologous stem cell transplantation (ASCT) for newly diagnosed multiple myeloma (MM) has been questioned due to…
The proteasome inhibitor carfilzomib has been investigated for the treatment of relapsed/refractory multiple myeloma (MM) in two Phase III clinical…
The American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA presented exciting results from the ASPIRE…
The American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, presented exciting data on the use…
Treating cancer beyond progression is an important option to be considered in cases where the benefits outweigh the risks. Speaking…
An update on the results of the Phase III ECHELON-1 study (NCT01712490), comparing ABVD vs. AVD plus brentuximab vedotin in…
CAR T-cells are a particularly exciting therapeutic area, which was widely covered at the American Society of Hematology (ASH) 2017…
Following on from the success of brentuximab vedotin, new antibody-drug conjugates (ADCs) for lymphoma are on the horizon. These successors…
Ropeginterferon Alfa-2b Induces High Rates of Clinical, Hematological and Molecular Responses in PV Patients. Two – year results from the…
Anne S. Tsao, MD of MD Anderson Cancer Center discusses two reasons Osimertinib is good for first line treatment such…
Anne S. Tsao, MD of MD Anderson Cancer Center discusses third generation TKIs and how they cause less diarrhea, abdominal…
Anne S. Tsao, MD of MD Anderson Cancer Center discusses profiling standards for NSCLC blood & tissue especially for oncogenic…
Anne S. Tsao, MD of MD Anderson Cancer Center discusses Osimertinib in front-line for EGFR mutated resistance mechanisms and how…
Beth Eaby-Sandy, MSN, CRNP of University of Pennsylvania talks about the serious illness conversation guides and how they can be…
Vassiliki Papadimitrakopoulou, MD of MD Anderson Cancer Center discusses turning cold tumors into hot tumors using agents that address immune…
Anne S. Tsao, MD of MD Anderson Cancer Center discusses mesothelioma trends in 2018 with PrECOG and Ipi Nivo v…
Charles Rudin, MD, PhD of Memorial Sloan Kettering Cancer Center discusses small-cell lung cancer new approaches using immunotherapy. Small-cell lung…
Beth Eaby-Sandy, MSN, CRNP of University of Pennsylvania explains that in patient conversations with loved ones, it’s the best to…
Vassiliki Papadimitrakopoulou, MD of MD Anderson Cancer Center discusses NSCLC checkpoint inhibitors with the combinations of Epacadostat and IL-2 and…
Anne S. Tsao, MD of MD Anderson Cancer Center discusses the new salvage guidelines for mesothelioma, including pembrolizumab & ipilimumab…
Charles Rudin, MD, PhD of Memorial Sloan Kettering Cancer Center discusses Rovalpituzumab Tesirine (Rova-T) a DLL3 target in SCLC. According…
Vassiliki Papadimitrakopoulou, MD of MD Anderson Cancer Center discusses checkpoint inhibitors as first line therapy, pembrolizumab alone and in combination…
Beth Eaby-Sandy, MSN, CRNP of University of Pennsylvania discusses patient conversation management and the “I hope but I worry” phrase.…
Dr. Anne S. Tsao, MD of MD Anderson Cancer Center discusses about their study of LUME-MESO Trial for mesothelioma treatment.…
Charles Rudin, MD, PhD of Memorial Sloan Kettering Cancer Center discusses Osimertinib, its real world toxicity issues and comparison with…
Beth Eaby-Sandy, MSN, CRNP of University of Pennsylvania discusses barriers to patient communication advertising, clinical jargon, and encouraging hopeful messages,…
Vassiliki Papadimitrakopoulou, MD of MD Anderson Cancer Center discusses the 2018 significant NSCLC trials including EMPOWER, KEYNOTE-189, & MYSTIC. This…
Anne S. Tsao, MD of MD Anderson Cancer Center discusses IFCT MAPS trial, the PFS and overall benefit in front-line…
Charles Rudin, MD, PhD of Memorial Sloan Kettering Cancer Center talks about using Osimertinib in first line and possible shift…
Advanced Forms of MPNs are Associated with Chromosomal Abnormalities Involved in Disease Progression
Joshua Bauml, MD of the University of Pennsylvania discusses thoracic oncology in 2018 and the importance of finding better biomarkers.…
Jessica S. Donington, MD of NYU Langone Health discusses pre-operative questions for NSCLC patient treatment. Determining resectable patients from a…
Joshua Bauml, MD of the University of Pennsylvania discusses Osimertinib versus Erlotinib or Gefitinib in the FLAURA Trial. Osimertinib did…
Jessica S. Donington, MD of NYU Langone Health talks about the IASLC Lung Cancer Staging Project and why some factors…
Joshua Bauml, MD of the University of Pennsylvania discusses the next generation sequencing assays that will allow more targeting in…
Jessica S. Donington, MD of NYU Langone Health discusses IASLC lung cancer staging project, important changes and complexities. There are…
Joshua Bauml, MD of the University of Pennsylvania discusses MET Exon 14 Skipping Mutations and Crizotinib. This is an important…